The most comprehensive and go-to place for all short selling reseach reports online.
Currently a total of 275 research reports from 14 investment research firms has been aggregated, with new reports being added and updated constantly
ALL
Fuzzy Panda Research(8)
Hindenburg Research(52)
MuddyWaters(44)
Blue Orca Capital(35)
Gotham City Research LLC(11)
Anonymous Analytics(5)
J Capital Research(26)
Grizzly Research LLC(22)
Jehoshaphat Research(10)
Culper Research(20)
Ningi Research(4)
Night Market Research(14)
Ontake Research(2)
Bonitas Research(22)
https://www.hindenburgresearch.com/
https://www.hindenburgresearch.com/
ALL
1636(1)
AMEH(1)
APHA(1)
BE(1)
CLOV(1)
CRIUF(1)
CSSE(1)
DKNG(1)
DVA(1)
EBON(1)
ENOB(1)
EROS(1)
FD(1)
GNPX(1)
GNUS(1)
GNW(1)
GRWG(1)
HFFG(1)
HMBL(1)
IDEX(1)
INPX(1)
JCOM(1)
KNDI(1)
LOOP(1)
LTS(1)
MARA(1)
MULN(1)
N/A(1)
NEWP(1)
NEXCF(1)
NKLA(1)
NTRA(1)
OPK(1)
OPRA(1)
ORA(1)
PCLO(1)
PCYO(1)
PGLC(1)
PLSE(1)
PRED(1)
RIDE(1)
RIOT(1)
SDC(1)
SGLY(1)
SKYS(1)
SLI(1)
SRNE(1)
TGLS(1)
TWTR(1)
WINS(1)
WORX(1)
YRIV(1)
Current Share Price: 15.130
Hindenburg Research
Initial Report Date(2018/04/24)Share Price:17.300
Initial Report Date(2018/04/24)Share Price:17.300
Pulse Biosciences: Failed FDA Clearance, New SEC Investigation, And An Uncertain Path Forward
Details Link > Pulse failed to achieve an FDA 510(k) clearance which it had previously described as a “foundation for future clearances”. The current direction of the company seems highly uncertain.
The company and several directors have been subpoenaed as part a newly disclosed SEC investigation into potential insider trading around a company news release.
Any future avenues are likely to be capital-intensive. Per the 10-K, “…we plan to raise additional capital in the future”.
Bottom line: Pulse is focused on a technology that doesn’t seem to work well. Limited oncological studies show poor to mixed results. Aesthetic applications thus far have insignificant potential.
We think Pulse is stuck in a precarious position, and the current stock price in no way reflects the risks, capital needs, and the looming regulatory overhang facing the company.
By wantattse
Start